These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 14633725

  • 1. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW, Poole DJ, Aarts WM, Gómez Yafal A, Gritz L, Schlom J.
    Cancer Res; 2003 Nov 15; 63(22):7942-9. PubMed ID: 14633725
    [Abstract] [Full Text] [Related]

  • 2. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.
    Clin Cancer Res; 2003 May 15; 9(5):1837-49. PubMed ID: 12738742
    [Abstract] [Full Text] [Related]

  • 3. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM, Schlom J, Hodge JW.
    Cancer Res; 2002 Oct 15; 62(20):5770-7. PubMed ID: 12384537
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
    Greiner JW, Zeytin H, Anver MR, Schlom J.
    Cancer Res; 2002 Dec 01; 62(23):6944-51. PubMed ID: 12460911
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
    Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J.
    J Clin Oncol; 2005 Feb 01; 23(4):720-31. PubMed ID: 15613691
    [Abstract] [Full Text] [Related]

  • 7. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
    Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J.
    Clin Cancer Res; 2005 Feb 15; 11(4):1597-607. PubMed ID: 15746065
    [Abstract] [Full Text] [Related]

  • 8. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C, Schlom J, Hodge JW.
    Clin Cancer Res; 2005 Mar 15; 11(6):2416-26. PubMed ID: 15788693
    [Abstract] [Full Text] [Related]

  • 9. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
    Hodge JW, Higgins J, Schlom J.
    Vaccine; 2009 Jul 16; 27(33):4475-82. PubMed ID: 19450631
    [Abstract] [Full Text] [Related]

  • 10. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
    Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA.
    Cancer Res; 1995 Aug 15; 55(16):3598-603. PubMed ID: 7543017
    [Abstract] [Full Text] [Related]

  • 11. A triad of costimulatory molecules synergize to amplify T-cell activation.
    Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J.
    Cancer Res; 1999 Nov 15; 59(22):5800-7. PubMed ID: 10582702
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK.
    Clin Cancer Res; 2005 Apr 15; 11(8):3017-24. PubMed ID: 15837756
    [Abstract] [Full Text] [Related]

  • 13. Technology evaluation: CEA-TRICOM, Therion Biologics Corp.
    Morse MA.
    Curr Opin Mol Ther; 2001 Aug 15; 3(4):407-12. PubMed ID: 11525565
    [Abstract] [Full Text] [Related]

  • 14. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
    Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY.
    Cancer Res; 2001 May 01; 61(9):3725-34. PubMed ID: 11325845
    [Abstract] [Full Text] [Related]

  • 15. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
    Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW.
    Cancer Res; 1999 Feb 01; 59(3):676-83. PubMed ID: 9973217
    [Abstract] [Full Text] [Related]

  • 16. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M.
    Virus Res; 2006 Mar 01; 116(1-2):11-20. PubMed ID: 16214252
    [Abstract] [Full Text] [Related]

  • 17. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
    Duggan MC, Jochems C, Donahue RN, Richards J, Karpa V, Foust E, Paul B, Brooks T, Tridandapani S, Olencki T, Pan X, Lesinski GB, Schlom J, Carson Iii WE.
    Cancer Immunol Immunother; 2016 Nov 01; 65(11):1353-1364. PubMed ID: 27581603
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.
    Kantor J, Irvine K, Abrams S, Snoy P, Olsen R, Greiner J, Kaufman H, Eggensperger D, Schlom J.
    Cancer Res; 1992 Dec 15; 52(24):6917-25. PubMed ID: 1458480
    [Abstract] [Full Text] [Related]

  • 19. Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
    Kudo-Saito C, Schlom J, Hodge JW.
    Clin Cancer Res; 2004 Feb 01; 10(3):1090-9. PubMed ID: 14871989
    [Abstract] [Full Text] [Related]

  • 20. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines.
    Hodge JW, Schlom J.
    Cancer Res; 1999 Oct 15; 59(20):5106-11. PubMed ID: 10537283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.